tbuckley/cabot-search huggingface dataset:
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Authors: Bao Wang, Neeta Abraham, Guodong Gao, Qian Yang
Journal: Translational Neurodegeneration (2016)

Parkinson's disease (PD) is the second most common neurodegenerative disease. Increasing evidence supports that dysregulation of autophagy and mitochondrial function are closely related with PD pathogenesis. In this review, we briefly summarized autophagy pathway, which consists of macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). Then, we discussed the involvement of mitochondrial dysfunction in PD pathogenesis. We specifically reviewed the recent developments in the relationship among several PD related genes, autophagy and mitochondrial dysfunction, followed by the therapeutic implications of these pathways. In conclusion, we propose that autophagy activity and mitochondrial homeostasis are of high importance in the pathogenesis of PD. Better understanding of these pathways can shed light on the novel therapeutic methods for PD prevention and amelioration.
Safety-Net Hospitals Care—Reply
Authors: Richard S. Hoehn, Derek E. Go, Shimul A. Shah
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
EXPERIENCIA EN CPRE EN PACIENTES DE EDAD MENOR A 18 AÑOS EN UN SERVICIO DE ADULTOS DE UN HOSPITAL DE TERCER NIVEL
Authors: J Mostazo Torres, IL Pinazo Martinez, M Vilchez Jaimez
Journal: Endoscopy (2016)

La colangiopancreatografía retrógrada endoscópica (CPRE) es una reconocida herramienta diagnóstica y terapéutica cuyo uso en las dos primeras décadas de la vida es cada vez más común, existiendo pocos datos sobre la seguridad y utilidad de este procedimiento en ellos.
TCT-137 Influence of non-culprit lesions management on outcomes in patients over 75 years old with ST elevated myocardial infarction. Results from the ESTROFA MI+75 nation-wide registry
Authors: Jose M. de la Torre Hernandez, Joan Antoni Gomez Hospital, Salvatore Brugaletta, jose antonio baz, Armando Perez de Prado, Ramon Lopez Palop, Ana Belen Cid Alvarez, Tamara Garcia Camarero, Alejandro Diego Nieto, Federico Gimeno, Jose Antonio Fernandez Diaz, Juan Sanchis Fores, Fernando Alfonso, Roberto Blanco, Javier Botas, Javier Navarro Cuartero, Jose Moreu Burgos, Francisco Bosa, Jose Miguel Vegas, Jaime Elizaga, Antonio Luis Arrebola Moreno, Joseantonio Linares Vicente, Felipe Hernandez, Neus Salvatella Giralt, Marta Monteagudo, Alfredo Gomez Jaume, Xavier Carrillo, Roberto Martin-Reyes, Fernando Lozano, Jose Rumoroso, leire andraka, Antonio J. Dominguez
Journal: Journal of the American College of Cardiology (2016)
Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study
Authors: Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J. Dore, Gail V. Matthews
Journal: Hepatology (2016)

While interferon-based therapy has excellent efficacy in acute and recent hepatitis C virus (HCV) infection, the side effect profile limits implementation. Sofosbuvir and ribavirin for 12-24 weeks is safe and well tolerated in chronic HCV, with efficacy dependent on genotype and disease stage. The aim of this study was to assess the efficacy of sofosbuvir and ribavirin for 6 weeks in individuals with recent HCV infection. In this open-label study conducted in Australia and New Zealand, adults with recent HCV (duration of infection <12 months) received sofosbuvir 400 mg daily and weight-based ribavirin (<75 kg, 1,000 mg/day; ≥75 kg, 1,200 mg/day) for 6 weeks. The primary efficacy endpoint was sustained virological response at posttreatment week 12 (SVR12). Nineteen participants commenced sofosbuvir and ribavirin (89% male, 74% with human immunodeficiency virus, 68% genotype 1a). Four (21%) reported a symptomatic HCV seroconversion illness, including 2 with jaundice. At baseline, median HCV RNA was 5.4 log10 IU/mL (interquartile range 4.4-6.8) and median estimated duration of infection was 37 weeks (interquartile range 27-41). At the end of treatment, HCV RNA was nonquantifiable in 89% (n = 17). SVR4 and SVR12 were 42% (n = 8) and 32% (n = 6), respectively. Treatment failure was due to nonresponse (n = 2), posttreatment relapse (n = 9), reinfection (n = 1), and loss to follow-up (n = 1). The regimen was well tolerated with minimal hematological toxicity. SVR12 was related to baseline HCV RNA (≤6 log10 IU/mL, P = 0.018) and early on-treatment viral kinetics (HCV RNA below the level of quantitation at week 1, P = 0.003).Six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was suboptimal; further research is needed to determine whether more potent interferon-free direct-acting antiviral regimens will allow treatment duration to be shortened in recent, predominantly asymptomatic HCV infection. (Hepatology 2016;64:1911-1921).
TCT-204 Optimal duration of dual antiplatelet therapy (DAPT) after second generation drug-eluting stent (DES) implantation in elderly patients: the SECURITY-ELDERLY substudy
Authors: Luca Angelo Ferri, Alaide Chieffo, Gennaro Giustino, Arian Frasheri, Roberto Garbo, Monica Masotti-Centol, Neus Salvatella, Juan Francisco Oteo Dominguez, Luigi Steffanon, Giuseppe Tarantini, Patrizia Presbitero, Alberto Menozzi, Edoardo Pucci, Josepa Mauri, Gennaro Sardella, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
TCT-393 Long-term Outcomes of Repeated Paclitaxel-coated Balloon Angioplasty for Recurrent Restenosis Lesions after Paclitaxel-coated Balloon Angioplasty for In-stent Restenosis
Authors: Keiichiro Iwasaki, Kazushige Kadota, Akimune Kuwayama, katsuya miura, Masanobu Ohya, Takenobu Shimada, Shunsuke Kubo, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto
Journal: Journal of the American College of Cardiology (2016)
Routine vs Selective Invasive Strategies in Acute Coronary Syndromes
Authors: Anthony A Bavry, Dharam J Kumbhani
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neural Substrates of Overgeneralized Conditioned Fear in PTSD
Authors: Antonia N. Kaczkurkin, Philip C. Burton, Shai M. Chazin, Adrienne B. Manbeck, Tori Espensen-Sturges, Samuel E. Cooper, Scott R. Sponheim, Shmuel Lissek
Journal: American Journal of Psychiatry (2016)

Heightened generalization of fear from an aversively reinforced conditioned stimulus (CS+, a conditioned danger cue) to resembling stimuli is widely accepted as a pathogenic marker of posttraumatic stress disorder (PTSD). Indeed, a distress response to benign stimuli that "resemble" aspects of the trauma is a central feature of the disorder. To date, the link between overgeneralization of conditioned fear and PTSD derives largely from clinical observations, with limited empirical work on the subject. This represents the first effort to examine behavioral and brain indices of generalized conditioned fear in PTSD using systematic methods developed in animals known as generalization gradients: the gradual decline in conditioned responding as the presented stimulus gradually differentiates from CS+.Gradients of conditioned fear generalization were assessed using functional MRI and behavioral measures in U.S. combat veterans who served in Iraq or Afghanistan and had PTSD (N=26), subthreshold PTSD (N=19), or no PTSD (referred to as trauma control subjects) (N=17). Presented stimuli included rings of graded size, with extreme sizes serving as CS+ (paired with shock) and as a nonreinforced conditioned stimulus (CS-, a conditioned safety cue), and with intermediate sizes forming a continuum of similarity between CS+ and CS-. Generalization gradients were assessed as response slopes from CS+, through intermediate ring sizes, to CS-, with less steep slopes indicative of stronger generalization.Relative to trauma control subjects, PTSD patients showed stronger conditioned generalization, as evidenced by less steep generalization gradients in both behavioral risk ratings and brain responses in the left and right anterior insula, left ventral hippocampus, dorsolateral and dorsomedial prefrontal cortex, and caudate nucleus. Severity of PTSD symptoms across the three study groups was positively correlated with levels of generalization at two such loci: the right anterior insula and left ventral hippocampus.The results point to evidence of brain-based markers of overgeneralized fear conditioning related to PTSD. These findings provide further understanding of a central yet understudied symptom of trauma-related psychopathology.
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Authors: Harpreet Singh, Michael Brave, Julia A. Beaver, Joyce Cheng, Shenghui Tang, Eias Zahalka, Todd R. Palmby, Rajesh Venugopal, Pengfei Song, Qi Liu, Chao Liu, Jingyu Yu, Xiao Hong Chen, Xing Wang, Yaning Wang, Paul G. Kluetz, Selena R. Daniels, Elektra J. Papadopoulos, Rajeshwari Sridhara, Amy E. McKee, Amna Ibrahim, Geoffrey Kim, Richard Pazdur
Journal: Clinical Cancer Research (2016)

On April 25, 2016, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior antiangiogenic therapy. The approval was based on data from one randomized, open-label, multicenter study in which patients with RCC who had received prior antiangiogenic therapy were treated with either cabozantinib 60 mg orally once daily (n = 330) or everolimus 10 mg orally once daily (n = 328). The major efficacy outcome measure was progression-free survival (PFS) as assessed by a blinded independent radiology review committee in the first 375 randomized patients. A statistically significant improvement in PFS was seen, with a median PFS of 7.4 and 3.8 months in the cabozantinib and everolimus arms, respectively [hazard ratio (HR), 0.58; 95% confidence interval (CI), 0.45-0.74; P < 0.0001]. At a second interim analysis, a statistically significant improvement in overall survival (OS) in the intent-to-treat population was also demonstrated, with a median OS of 21.4 and 16.5 months in the cabozantinib and everolimus arms, respectively (HR, 0.66; 95% CI, 0.53-0.83; P = 0.0003). The most common (greater than or equal to 25%) adverse reactions included diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, hypertension, vomiting, weight loss, and constipation. Clin Cancer Res; 23(2); 330-5. ©2016 AACR.
TCT-303 Redefining Success in Hybrid Chronic Total Occlusion Angioplasty
Authors: James Sapontis, John Spertus, Robert Yeh, David Cohen, William Lombardi, Dimitri Karmpaliotis, Jeffrey Moses, William Nicholson, Ashish Pershad, R. Michael Wyman, Tony Spaedy, Stephen Cook, Parag Doshi, Robert Federici, Craig Thompson, Karen Nugent, Kensey Gosch, Steven Marso, J. Aaron Grantham
Journal: Journal of the American College of Cardiology (2016)
Perioperative Management of Localized Kidney Cancer
Authors: Martin H. Voss, Robert J. Motzer
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction
Authors: Dagmar M. Ouweneel, Erlend Eriksen, Krischan D. Sjauw, Ivo M. van Dongen, Alexander Hirsch, Erik J.S. Packer, M. Marije Vis, Joanna J. Wykrzykowska, Karel T. Koch, Jan Baan, Robbert J. de Winter, Jan J. Piek, Wim K. Lagrand, Bas A.J.M. de Mol, Jan G.P. Tijssen, José P.S. Henriques
Journal: Journal of the American College of Cardiology (2016)
TCT-428 Bioresorbable Coronary Devices in Clinical Practice: 6-month Results of the Prospective REPARA Registry
Authors: Felipe Hernandez, Eduardo Pinar Bermudez, Eduardo Molina, Jose Diaz, Neus Salvatella, Juan Carlos Fernández, Hipolito Gutierrez, Ramon Lopez Palop, Xavier Carrillo, Javier Zueco, Joan Antoni Gomez Hospital, Andres Iñiguez, Pedro Canas da Silva, Cristobal Urbano, Ramiro Trillo, Amparo Benedicto, Armando Perez de Prado, Vasco Gama Ribeiro, Henrique Gabriel, Pablo Salinas, Juan Sanchis Fores, Jose Rumoroso, Pablo Pinon, Pablo Avanzas, Jose Ramon Lopez Minguez, Monica Masotti, Raul Moreno, Iñigo Lozano
Journal: Journal of the American College of Cardiology (2016)
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Authors: Josef S Smolen, Joel M Kremer, Carol L Gaich, Amy M DeLozier, Douglas E Schlichting, Li Xie, Ivaylo Stoykov, Terence Rooney, Paul Bird, Juan Miguel Sánchez Bursón, Mark C Genovese, Bernard Combe
Journal: Annals of the Rheumatic Diseases (2016)

Objectives To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs). Methods In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables. Results 527 patients were randomised (placebo, 176; baricitinib 2 mg, 174; baricitinib 4 mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4 mg than 2 mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI &lt;0.5; p≤0.001), reductions in fatigue (FACIT-F ≥3.56; p≤0.05), improvements in PtGA (p≤0.001) and pain (p≤0.001) and reductions in duration of MJS (p&lt;0.01). Conclusions Baricitinib improved most PROs through 24 weeks compared with placebo in this study of treatment-refractory patients with previously inadequate responses to bDMARDs, including at least one TNFi. PRO results aligned with clinical efficacy data for baricitinib. Trial registration number NCT01721044 ; Results.
Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma
Authors: Beatriz Sanchez-Vega, Santiago Barrio, Yanira Ruiz, Ramon Garcia-Sanz, Bruno Paiva, Carlos Marin, Roberto Maldonado, Inmaculada Rapado, Jose Cervera, Rosa M. Ayala, Teresa Cedena, Cristina Jimenez, Miguel T Hernandez, Rafael Martinez, Enrique M Ocio, M Asuncion Echeveste, Laura Rosinol, Joan Blade, Maria-Victoria Mateos, Jesus San Miguel, Juan Jose Lahuerta, Joaquin Martinez Lopez
Journal: Blood (2015)
The Involvement of Regulatory T Cells in Immunopathophysiology of Autoimmune Neutropenia in Infancy.
Authors: Kazuhiro Nakamura, Mizuka Miki, Hiroshi Kawaguchi, Takashi Sato, Emi Kurita, Rie Onodera, Asako Hiraoka, Masao Kobayashi
Journal: Blood (2006)
TCT-820 Multivessel Intracoronary Infusion of Allogeneic Cardiosphere Derived Cells in Dilated Cardiomyopathy: Long Term Outcomes of the Dilated Cardiomyopathy Intervention with Allogeneic Myocardially-Regenerative Cells (DYNAMIC Trial)
Authors: Tarun Chakravarty, Raj Makkar, Timothy Henry, Michelle Kittleson, John Friedman, Daniel Berman, Joao Lima, Konstantinos Malliaras, Robert Siegel, Leandro Slipczuk, Jeff Rudy, Eduardo Marban, Janice Pogoda, Linda Marban, Deborah Ascheim
Journal: Journal of the American College of Cardiology (2016)
TCT-74 A Serial 3- and 9-year Optical Coherence Tomography Assessment of Vascular Healing Response to Sirolimus- and Paclitaxel-Eluting Stents
Authors: Mariusz Tomaniak, Janusz Kochman, Lukasz Koltowski, Arkadiusz Pietrasik, Adam Rdzanek, Jacek Jąkała, Klaudia Proniewska, Krzysztof Malinowski, Krzysztof Filipiak, Grzegorz Opolski
Journal: Journal of the American College of Cardiology (2016)
Overview of French Routine Clinical Practice for the Management of Chemotherapy-Induced Anemia (CIA) with Biosimilar Epoetin Alfa in 563 Patients with Lymphoid Malignancies: A National Observational Study (The OncoBOS study)
Authors: Lionel Karlin, Jean-Philippe Metges, Nataliya Khobta, Gilles Boschetti, Alain Toledano, Camille Aubron-Olivier, Domitille Fernet, Olivier Fitoussi
Journal: Blood (2015)
Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells
Authors: Dong Woo Kang, Shin Wha Lee, Won Chan Hwang, Bo Hui Lee, Yong-Seok Choi, Young-Ah Suh, Kang-Yell Choi, Do Sik Min
Journal: Cancer Research (2016)

The RB1/E2F1 signaling pathway is frequently deregulated in colorectal cancer and has been suggested to intersect with Wnt/β-catenin and PI3K/Akt pathways, but molecular evidence for this link is lacking. In this study, we demonstrate that phospholipase D1 (PLD1), a transcriptional target of β-catenin/TCF4, orchestrates functional interactions between these pathways during intestinal tumor development. Overexpression of PLD1 in intestinal epithelial cells protected cells from apoptosis induced by PLD1 ablation in the Apcmin/+ mouse model of intestinal tumorigenesis. Mechanistic investigations revealed that genetic and pharmacologic targeting of PLD1 promote the E2F1-dependent apoptotic program via both miR-192/4465-mediated downregulation of RB1 and inhibition of Akt-TopBP1 pathways. Moreover, the miRNA-RB1 axis and Akt pathway also contributed to the PLD1-mediated self-renewal capacity of colon cancer-initiating cells. Finally, PLD1-driven E2F1 target gene expression positively correlated with tumor stage in patients with colorectal cancer. Overall, our findings suggest that PLD1 mediates cross-talk between multiple major signaling pathways to promote the survival and malignancy of colon cancer cells and may therefore represent an ideal signaling node for therapeutic targeting. Cancer Res; 77(1); 142-52. ©2016 AACR.